These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29500706)

  • 1. Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
    Mott DJ
    Patient; 2018 Jun; 11(3):249-252. PubMed ID: 29500706
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-centric HTA: different strokes for different folks.
    Mühlbacher AC
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):591-7. PubMed ID: 25896756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy.
    Mott DJ; Najafzadeh M
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):33-9. PubMed ID: 26560704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying Preferences in Drug Benefit-Risk Decisions.
    Tervonen T; Angelis A; Hockley K; Pignatti F; Phillips LD
    Clin Pharmacol Ther; 2019 Nov; 106(5):955-959. PubMed ID: 30929257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment.
    Hailey D
    Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on Health Technology Assessment (HTA): Good Practices & Principles. FIFARMA's Position on HTA Processes in Latin America: The Devil Is in the Details.
    Levy A
    Value Health Reg Issues; 2017 Dec; 14():53-56. PubMed ID: 29254542
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.
    Jackson Y; Janssen E; Fischer R; Beaverson K; Loftus J; Betteridge K; Rhoten S; Flood E; Lundie M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):383-396. PubMed ID: 31070048
    [No Abstract]   [Full Text] [Related]  

  • 9. Health Preference Research: An Overview.
    Craig BM; Lancsar E; Mühlbacher AC; Brown DS; Ostermann J
    Patient; 2017 Aug; 10(4):507-510. PubMed ID: 28597377
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of health technology assessment in China: New challenges.
    Chen Y; He Y; Chi X; Wei Y; Shi L
    Biosci Trends; 2018; 12(2):102-108. PubMed ID: 29760354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
    Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
    Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.
    Feig C; Cheung KL; Hiligsmann M; Evers SMAA; Simon J; Mayer S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):223-232. PubMed ID: 28862060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment for radiologists: basic principles and evaluation framework.
    Lim ME; O'Reilly D; Tarride JE; Burke N; Ferrusi IL; Campbell K; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):299-306. PubMed ID: 19394570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most important barriers and facilitators of HTA usage in decision-making in Europe.
    Cheung KL; Evers SMAA; De Vries H; Levy P; Pokhrel S; Jones T; Danner M; Wentlandt J; Knufinke L; Mayer S; Hiligsmann M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):297-304. PubMed ID: 29303374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
    Whichello C; Bywall KS; Mauer J; Stephen W; Cleemput I; Pinto CA; van Overbeeke E; Huys I; de Bekker-Grob EW; Hermann R; Veldwijk J
    Health Policy; 2020 Dec; 124(12):1325-1332. PubMed ID: 32839011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community views and perspectives on public engagement in health technology assessment decision making.
    Wortley S; Tong A; Howard K
    Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health technology assessment and primary data collection for reducing uncertainty in decision making.
    Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
    J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.